Elamipretide

At a glance

---

What is Elamipretide?

Elamipretide (also known as SS-31, Bendavia, or MTP-131) is a synthetic tetrapeptide -- a chain of just 4 amino acids (D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine) -- designed by Hazel Szeto and Peter Bhatt at Weill Cornell Medical College in 2004.^[1] It was specifically engineered to do something no previous drug had done: cross cell membranes, accumulate in mitochondria, and directly stabilize the inner mitochondrial membrane.

The molecule is a proof of concept for an entire therapeutic approach. Mitochondrial dysfunction is implicated in hundreds of diseases -- from heart failure to neurodegeneration to the aging process itself -- but targeting the inner mitochondrial membrane with a drug had been considered essentially impossible. Elamipretide demonstrated that a small, cell-permeable peptide could concentrate 1,000 to 5,000 fold inside mitochondria and bind selectively to cardiolipin, a phospholipid found nowhere else in the body except the inner mitochondrial membrane.^[4]

In September 2025, elamipretide became the first mitochondria-targeted peptide to receive FDA approval, under the brand name FORZINITY, for the treatment of Barth syndrome -- a rare genetic condition caused by mutations in the tafazzin gene that impair cardiolipin remodeling.^[8] This was an accelerated approval, meaning the FDA determined the drug was reasonably likely to provide clinical benefit based on available evidence, but required confirmatory trials to maintain approval.

Why this matters beyond Barth syndrome: Elamipretide's approval validates the concept that mitochondria can be therapeutically targeted with peptides. Phase 3 trials are ongoing for dry age-related macular degeneration (AMD) and primary mitochondrial myopathy, and the preclinical literature suggests potential in heart failure, ischemia-reperfusion injury, and aging. But potential is not proof, and each indication requires its own clinical evidence.

---

How it works

In plain terms, elamipretide works by getting inside your cells, concentrating in the mitochondria, and stabilizing the molecular machinery that produces cellular energy. It does this by binding to a specific molecule called cardiolipin -- a phospholipid that exists only on the inner mitochondrial membrane and is essential for the proper function of the electron transport chain.^[4]

When cardiolipin is damaged or deficient (as in Barth syndrome, aging, or ischemia), the electron transport chain becomes "leaky" -- electrons escape and react with oxygen to create reactive oxygen species (ROS), which cause further mitochondrial damage in a vicious cycle. Elamipretide breaks this cycle by stabilizing the cardiolipin-cytochrome c interaction, keeping the electron transport chain properly organized and reducing electron leak.^[5]

Detailed mechanism (for advanced readers)

Elamipretide's mechanism has been extensively characterized across multiple labs:

• Cell permeability: The alternating aromatic-cationic motif (D-Arg-Dmt-Lys-Phe) allows elamipretide to cross cell membranes without requiring a transporter. The D-arginine and modified tyrosine (Dmt) residues are critical for this property. Cellular uptake is rapid and energy-independent.^[2]
• Mitochondrial concentration: Once inside the cell, elamipretide concentrates 1,000-5,000 fold in mitochondria. This concentration is driven by the mitochondrial membrane potential (negative inside) attracting the positively charged peptide, combined with specific binding to cardiolipin.^[3]
• Cardiolipin binding: Elamipretide binds selectively to cardiolipin through electrostatic and hydrophobic interactions. Cardiolipin is a unique phospholipid with four fatty acid chains that is found exclusively on the inner mitochondrial membrane. It serves as a structural anchor for electron transport chain complexes and is essential for their proper assembly and function.^[4]
• Electron transport chain stabilization: By binding cardiolipin, elamipretide stabilizes the interaction between cardiolipin and cytochrome c, which is critical for electron transfer between Complex III and Complex IV. This reduces electron leak, lowers ROS production, and improves ATP synthesis efficiency.^[5]
• ROS reduction: Unlike traditional antioxidants that scavenge existing ROS, elamipretide prevents ROS formation at the source by maintaining electron transport chain integrity. This is a fundamentally different and potentially more effective approach to reducing oxidative stress.

How it differs from other mitochondrial compounds: Unlike CoQ10 or MitoQ (which act as electron carriers or antioxidant scavengers), elamipretide works structurally -- it stabilizes the membrane architecture that keeps the electron transport chain functioning properly. Unlike MOTS-c (a mitochondria-derived peptide that acts as a signaling molecule), elamipretide directly targets the inner membrane. Unlike NAD+ precursors (NMN, NR), which support mitochondrial function through the sirtuin/NAD+ pathway, elamipretide acts at the level of the membrane itself.

---

What the research says

Elamipretide has the most robust evidence base of any mitochondria-targeted peptide. It is the only one with FDA approval, the only one with Phase 3 clinical trials, and the only one with a well-characterized molecular target validated across multiple independent labs. The question is not whether the mechanism works -- it's how broadly the therapeutic benefits extend beyond Barth syndrome.

Research timeline

Elamipretide's research history spans two decades, culminating in the first FDA approval for a mitochondria-targeted peptide:

Human clinical trials

Elamipretide's clinical program is more extensive than any other mitochondria-targeted peptide, with multiple Phase 2 trials completed and Phase 3 trials ongoing. The pivotal data for Barth syndrome led to FDA accelerated approval in September 2025.

Animal studies

The preclinical evidence base includes over 50 published studies across multiple independent laboratories worldwide. This is a critical distinction from many peptides where research is concentrated in a single lab or institution. Key areas of investigation include cardiac ischemia-reperfusion, heart failure, renal injury, neurodegenerative disease, skeletal muscle aging, and mitochondrial disease models.

Key findings by area

• Cardiac ischemia-reperfusion: SS-31 reduces infarct size and preserves cardiac function in multiple models of myocardial ischemia-reperfusion injury. Mechanism involves preserving mitochondrial integrity and reducing ROS-mediated damage during reperfusion.^[2]
• Aging and skeletal muscle: One hour of SS-31 treatment reverses age-related mitochondrial dysfunction in skeletal muscle of aged mice, restoring energetics to near-young levels. Effects include improved mitochondrial coupling, reduced proton leak, and increased ATP production.^[10]
• Heart failure: SS-31 improves cardiac function in models of pressure-overload heart failure, diabetic cardiomyopathy, and aging-related cardiac dysfunction. Mechanism involves restoring cardiolipin content and electron transport chain function.^[5]
• Renal injury: Protective effects demonstrated in acute kidney injury (ischemia-reperfusion), unilateral ureteral obstruction, and diabetic nephropathy models. The cardiolipin stabilization mechanism appears relevant across organs.^[4]
• Neurodegenerative disease: Neuroprotective effects in models of Parkinson's disease (MPTP), ALS, and traumatic brain injury. The blood-brain barrier permeability of SS-31 makes it potentially relevant to CNS conditions.^[3]
• Barth syndrome models: In tafazzin-knockdown mice (modeling Barth syndrome), SS-31 restores mitochondrial ultrastructure, improves cardiac function, and normalizes cardiolipin-dependent enzyme activities. This data supported the clinical development path to FDA approval.^[5]

---

What the evidence shows

Elamipretide generates interest across several domains -- from its approved indication in Barth syndrome to broader claims about mitochondrial health and aging. Here's what the published evidence actually supports:

---

Safety & side effects

What research shows

Elamipretide has been evaluated in over 500 subjects across multiple clinical trials, providing a more substantial safety dataset than most peptides in the research community. The safety profile is generally favorable, with most adverse events being mild to moderate and related to the injection site.

The FDA reviewed the available safety data as part of the accelerated approval for Barth syndrome and determined it was sufficient to support approval, which represents a higher standard of safety review than any non-approved peptide has undergone.

Reported side effects

From published clinical trial data:

• Common: Injection site reactions (pain, redness, induration at the injection site)
• Occasional: Headache, nausea, fatigue
• Infrequent: Dizziness, upper respiratory tract infection
• Rare: Elevated creatinine (observed in some renal studies, unclear clinical significance)

What we don't know

Contraindications and interactions

Known contraindications (from prescribing information):

• Known hypersensitivity to elamipretide or any excipient
• Pregnancy (no adequate data; animal studies showed embryo-fetal toxicity at supratherapeutic doses)

Theoretical concerns (based on mechanism of action):

• Use in patients with compromised mitochondrial membrane potential (mechanism depends on membrane potential for uptake)
• Concurrent use with other agents affecting mitochondrial function (no interaction studies published)

Drug interactions: No formal drug interaction studies have been published. Given the peptide's mechanism of action at the mitochondrial membrane level (rather than through cytochrome P450 metabolism), significant pharmacokinetic interactions are considered unlikely, but this has not been formally evaluated.

---

How people use it

Elamipretide is fundamentally different from most peptides discussed in community forums: it is a prescription medication with FDA approval for a specific indication.

Approved use

• FORZINITY (elamipretide) is approved for the treatment of Barth syndrome in patients 1 year of age and older.
• Administration is via subcutaneous injection.
• Prescription is required and is typically managed by physicians specializing in mitochondrial disease or pediatric cardiology.

Clinical trial access

For indications other than Barth syndrome, elamipretide is available only through clinical trial enrollment:

• NuPOWER (NCT05162768): For patients with primary mitochondrial myopathy. Actively enrolling.
• ReNEW (NCT05488536): For patients with dry AMD and geographic atrophy. Actively enrolling.

---

Legal & regulatory status

As of March 2026:

United States (FDA)

Elamipretide is FDA-approved under accelerated approval (September 2025) for the treatment of Barth syndrome under the brand name FORZINITY. This makes it the first mitochondria-targeted peptide to receive FDA approval. It is a prescription medication -- not a supplement, not a research chemical.

Accelerated approval conditions: The FDA requires confirmatory clinical trials to verify and describe the clinical benefit. If confirmatory data does not verify clinical benefit, the FDA may initiate proceedings to withdraw approval. Phase 3 trials (NuPOWER, ReNEW) are underway and will provide additional data across indications.

European Union

Elamipretide is not approved by the European Medicines Agency (EMA). No marketing authorization application has been filed in the EU as of March 2026. Stealth BioTherapeutics has indicated plans for international regulatory filings but timelines have not been announced.

Other markets

Elamipretide is not approved in the UK, Australia, Canada, Japan, or other major markets.

WADA / USADA

Elamipretide is not specifically named on the WADA Prohibited List. However, because it is a prescription medication with potential performance-enhancing properties (improved mitochondrial function and cellular energetics), athletes should consult with anti-doping authorities before use. In jurisdictions where elamipretide is not approved for the athlete's condition, it may fall under Section S0 (Non-Approved Substances).

---

How Elamipretide compares

To understand elamipretide's position in the mitochondrial peptide landscape, here's how it compares to MOTS-c -- the other mitochondria-associated peptide that generates significant community interest:

This comparison is instructive. Both peptides are associated with mitochondria, and both generate significant community interest. But the evidence profiles could not be more different. Elamipretide has FDA approval, Phase 2-3 clinical data, a well-characterized molecular target validated across multiple labs, and over 500 human subjects in clinical trials. MOTS-c has essentially zero human clinical data despite considerable preclinical hype -- it is an endogenous mitochondria-derived peptide discovered in 2015 with interesting biology but no clinical development program.

The lesson: "mitochondrial peptide" is not a meaningful category for evaluating evidence. Each molecule must be assessed on its own data.

---

Related content

Peptide

MOTS-c Profile

Another mitochondria-associated peptide, but endogenously derived with a very different evidence profile. Zero human clinical trials despite preclinical interest.

Peptide

NAD+ Profile

A related molecule in the mitochondrial and cellular energy space. Different mechanism but overlapping interest community.

News

Kennedy Peptide Reclassification

Regulatory changes affecting the peptide landscape, including how approved peptides like elamipretide fit into the broader framework.

---

References

1. [1]

   Szeto HH. “Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases.” Ann N Y Acad Sci. 2008. 1147:112–121 PubMedReview

   Foundational review from the inventor describing the design rationale for the SS peptide series including SS-31.

2. [2]

   Zhao K, Zhao GM, Wu D, et al.. “Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury.” J Biol Chem. 2004. 279(33):34682–34690 DOI PubMedAnimal study

   First published characterization of SS-31 showing mitochondrial targeting, antioxidant activity, and cytoprotection. Seminal paper for the field.

3. [3]

   Szeto HH. “Mitochondria-targeted peptide antioxidants: novel neuroprotective agents.” AAPS J. 2006. 8(3):E521–E531 DOI PubMedReview

   Early review describing the SS peptide class mechanism of action, including mitochondrial concentration and ROS scavenging.

4. [4]

   Birk AV, Liu S, Soong Y, et al.. “The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.” J Am Soc Nephrol. 2013. 24(8):1250–1261 DOI PubMedAnimal study

   Key mechanistic study identifying cardiolipin as the specific binding target. Demonstrated SS-31 stabilizes cardiolipin-cytochrome c interaction and restores electron transport.

5. [5]

   Szeto HH. “First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.” Br J Pharmacol. 2014. 171(8):2029–2050 DOI PubMedReview

   Comprehensive review of elamipretide pharmacology. Covers cardiolipin binding, electron transport chain effects, and therapeutic applications across disease models.

6. [6]

   Stealth BioTherapeutics. “ReCLAIM-2: A Phase 2 randomized, double-blind, placebo-controlled trial of elamipretide in subjects with geographic atrophy.” ClinicalTrials.gov. 2022. LinkRCT

   Phase 2 RCT (n=176). Mixed results on primary endpoints but sufficient signal to support Phase 3 advancement.

7. [7]

   Stealth BioTherapeutics. “TAZPOWER: A Phase 2 trial of elamipretide in Barth syndrome.” ClinicalTrials.gov. 2025. LinkPilot study

   Pivotal study leading to FDA accelerated approval. Small sample size (n=12) typical for rare disease. Open-label crossover design.

8. [8]

   U.S. Food and Drug Administration. “FDA approves first treatment for Barth syndrome.” 2025. LinkReview

   FDA accelerated approval announcement. Confirmatory trial required to maintain approval status.

9. [9]

   Karaa A, Haas R, Goldstein A, et al.. “Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.” Neurology. 2018. 90(14):e1212–e1221 DOI PubMedRCT

   Phase 2 dose-escalation in PMM. Original MMPOWER-3 Phase 3 failed primary endpoint. Open-label extension showed improvements but was terminated in 2020.

10. [10]

    Siegel MP, Kruse SE, Percival JM, et al.. “Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice.” Aging Cell. 2013. 12(5):763–771 DOI PubMedAnimal study

    Demonstrated that SS-31 rapidly reverses age-related mitochondrial dysfunction in skeletal muscle within one hour of treatment. Key study for aging claims.

11. [11]

    Stealth BioTherapeutics. “NuPOWER: A Phase 3 study of elamipretide in primary mitochondrial myopathy.” ClinicalTrials.gov. 2025. LinkRCT

    Ongoing Phase 3 trial. Redesigned endpoints based on MMPOWER-3 learnings. Results pending.

12. [12]

    Stealth BioTherapeutics. “ReNEW: A Phase 3 study of elamipretide in dry AMD with geographic atrophy.” ClinicalTrials.gov. 2025. LinkRCT

    Ongoing Phase 3 trial building on ReCLAIM-2 data. Results pending.

---